New research identified DNA‑repair gene alterations as modifiers of response to combination chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC). The study examined how defects in homologous recombination and other repair pathways influence sensitivity to platinum‑based regimens and combination approaches, suggesting a potential framework for patient selection. Investigators recommend integrating genomic profiling into trial design to prospectively evaluate tailored regimens for VHL‑deficient and DNA‑repair‑altered PDAC subgroups.